Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +1 more source
Novel clinical trial designs emerging from the molecular reclassification of cancer
CA: A Cancer Journal for Clinicians, Volume 75, Issue 3, Page 243-267, May/June 2025.Abstract Next‐generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease,
Mina Nikanjam +4 more
wiley +1 more source
Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]
Journal of Lipid Research, 2013 Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a negative regulator of cell proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). Therefore, enhanced SMS activity could favor cell proliferation.
Tara Ann Burns +9 more
doaj
Application of chromosome microdissection probes for elucidation of BCR- ABL fusion and variant Philadelphia chromosome translocations in chronic myelogenous leukemia [PDF]
, 1993 Jianhao Zhang +4 more
openalex +1 more source
Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571 [PDF]
, 2017 Background: Chronic myeloid leukemia is caused by a chromosomal translocation that results in an oncogenic fusion protein, Bcr-Abl. Bcr-Abl is a tyrosine kinase whose activity is inhibited by the antineoplastic drug STI571.
Barni, Rossella +14 more
core
Labeling of v‐Src and BCR‐ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism [PDF]
, 1994 Hidesuke Fukazawa +5 more
openalex +1 more source
eLifePhiladelphia chromosome-positive (Ph+) leukemia is a fatal hematological malignancy. Although standard treatments with tyrosine kinase inhibitors (TKIs) have achieved remarkable success in prolonging patient survival, intolerance, relapse, and TKI ...
Mengya Zhao +10 more
doaj +1 more source
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy [PDF]
, 1994 JQ Guo +9 more
openalex +1 more source
Neue Ansätze des molekularen Targetings bei der Philadelphia-Chromosom-positiven Leukämie [PDF]
, 2011 In Philadelphia Chromosome (Ph) positive ALL and CML the fusion between BCR and ABL leads to the BCR/ABL fusion proteins, which induces the leukemic phenotype because of the constitutive activation of multiple signaling pathways down-stream to the ...
Mian, Afsar Ali
core
Relation of common ABL kinase domain mutations with resistance to Tyrosine Kinase Inhibiters in patients with Chronic Myeloid Leukemia in Middle Euphrates of Iraq [PDF]
, 2020 Background: Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease, associated with a reciprocal translocation between chromosomes 9 and chromosome 22, lead to the formation of the BCRABL fusion gene (Philadelphia chromosome).
Musawi, Mohammed Sadeq Mahdi Al-
core